Literature DB >> 34244680

Cost-effective benefit of iron-replacement therapy.

Gregory B Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34244680     DOI： 10.1038/s41569-021-00601-9

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.

Authors:  Pieter Martens; Matthias Dupont; Jeroen Dauw; Petra Nijst; Lieven Herbots; Paul Dendale; Pieter Vandervoort; Liesbeth Bruckers; Wai Hong Wilson Tang; Wilfried Mullens
Journal:  Eur Heart J       Date:  2021-12-21       Impact factor: 29.983

2.  Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.

Authors:  Phil McEwan; Piotr Ponikowski; Jason A Davis; Giuseppe Rosano; Andrew J S Coats; Fabio Dorigotti; Donal O'Sullivan; Antonio Ramirez de Arellano; Ewa A Jankowska
Journal:  Eur J Heart Fail       Date:  2021-06-30       Impact factor: 15.534
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.